Download Volume 5 Index

TECHNOLOGY, PRODUCTS, MARKETS AND SERVICE OPPORTUNITIES
A NEW MEDICINE PUBLICATION
VOLUME 5, NUMBER 1-12 INDEX
SEPTEMBER 2000
TABLE OF CONTENTS
LUNG CANCER SCREENING
STATE-OF-THE-ART IN
THE MANAGEMENT OF CANCER
KIDNEY CANCER — PART IV
IMMUNOTHERAPHY/TUMOR
VACCINES
ADOPTIVE IMMUNOTHERAPY
1022
1022
Tumor-infiltrating Lymphocytes
(TILs)
1022
Tumor-Sensitized Lymph
Node Cells
1023
Autolymphocyte Therapy (ALT)
1023
Dendritic Cells (DC)
1023
ACTIVE SPECIFIC IMMUNOTHERAPY
1024
Autologous Tumor Vaccines
1024
Autologous Tumor-Derived Heat
Shock Protein-Peptide Complex-96
(HSPPC) Vaccine
1024
Tumor-Specific, Mutated, von
Hippel-Lindau Peptides
1024
CD40 Ligand (CD40L)
1025
LUNG CANCER — PART I
ETIOLOGY AND GLOBAL
EPIDEMIOLOGY
GLOBAL EPIDEMIOLOGY
1041
TRIAD EPIDEMIOLOGY
1042
Low-dose Helical Computed
Tomography (CT)
1076
Surgery
1115
Sputum Cytology
1078
Radiation Therapy (RT)
1116
TREATMENT OF PRIMARY SCLC
1114
Breath Analysis
1079
Thoracic radiation therapy (RT) 1116
Molecular Markers
1079
Prophylactic cranial
irradiation (PCI)
1080
Brush Cytology
1080
Endoscopy/Bronchoscopy
1080
Biopsy
1083
Noninvasive Imaging
1083
Chemotherapy
1116
1117
Combination chemotherapy
1117
Single-agent chemotherapy
1118
Intensive chemotherapy/
chemoradiotherapy
1124
1126
Computed tomography (CT)
1083
Nuclear medicine
1083
MANAGEMENT OF
REFRACTORY/RELAPSED SCLC
1084
Drug Resistance in SCLC
1126
Second-line Chemotherapy
1127
HISTOLOGY AND CLASSIFICATION
LUNG CANCER — PART III
SMALL CELL LUNG CANCEREPIDEMIOLOGY, TUMOR MARKERS,
STAGING, PROGNOSIS, DISEASE
MONITORING, AND CURRENT
TREATMENT STRATEGIES
EPIDEMIOLOGY
1105
TUMOR MARKERS
1106
Gemcitabine
1127
Topotecan
1127
Paclitaxel
1127
LUNG CANCER — PART IV
NON-SMALL-CELL LUNG CANCEREPIDEMIOLOGY, TUMOR MARKERS,
DIAGNOSIS, STAGING, AND PROGNOSIS
Oncogenes and Tumor
Suppressor Genes
1106
Neuroendocrine Markers
1106
Gender Variations in the
Incidence of NSCLC
1129
1106
Age Factors in the Incidence
of NSCLC
1131
Stage at Diagnosis
1131
Survival
1131
NSCLC Incidence by
Histologic Type
1131
DIAGNOSIS, STAGING, PROGNOSIS
AND DISEASE MONITORING
Serum Markers
1107
1042
Lung Cancer in Europe
1042
Neuron-specific enolase
1108
Lung Cancer in Japan
1042
Pro-gastrin-releasing peptide
1108
1043
Chromogranin A
1108
1043
Multiple serum markers
1108
Tobacco Smoking
1114
1076
Lung Cancer in the USA
ETIOLOGY
Positron emission
tomography (PET)
Chest X-ray
PRESENTATION AND DIAGNOSIS
Lymphokine-activated Killer
(LAK) Cells
1074
TUMOR MARKERS
1129
1133
Environmental Factors
1045
Angiogenesis Markers
Hereditary Factors
1045
Detection of Tumor Cells
in Bone Marrow
1111
DIAGNOSIS AND SCREENING
1135
Noninvasive Imaging
1112
Noninvasive Imaging
1135
LUNG CANCER — PART II
SCREENING, DIAGNOSIS,
AND CLASSIFICATION
1109
EPIDEMIOLOGY
Bone Scans
1112
Scintigraphy
1112
Hereditary Factors
1133
Other Biomarkers
1135
Electron beam tomography
(EBT)
COPYRIGHT © 2000 NEW MEDICINE INC. UNAUTHORIZED PHOTOCOPYING, DISTRIBUTION OR ELECTRONIC STORAGE IS PROHIBITED BY LAW.
1135
FUTURE ONCOLOGY
Positron emission tomography
(PET)
In vitro Approaches
Curative Surgery
SEPTEMBER 2000
1150
1135
Minimally invasive surgery
1135
Video-assisted thoracic surgery
(VATS)
1152
Spindle Poisons
1191
Anhydrovinblastine
1191
BMS-184476
1191
1152
Maytansinoid
immunoconjugates
1191
1153
PG-TXL
1192
1153
Taxoprexin
1192
T67
1192
1151
Cell-associated transferrin
receptor (TfR)
1135
Cyfra 21-1
1135
DR-70
1136
External Beam Radiotherapy
1136
Intensity Modulated Radiation
Therapy (IMRT)
1155
Brachytherapy
1155
Exatecan mesylate
1192
1155
TAS-103
1192
1155
XR5000
1193
1156
Antifolates
1193
1156
Alimta
1193
S-1
1193
Gastrin-releasing protein
receptor (GRPr)
Surgery in Lung Metastases
RADIOTHERAPY (RT)
Heterogeneous nuclear
ribonucleoprotein (hnRNP)
A2/B1
1136
Intraluminal brachytherapy
Homeobox (HOX) genes
1141
Intraoperative brachytherapy
MAb 28K29
1142
Micrometastases detection
1142
Proton-beam Radiotherapy
CHEMOTHERAPY
Types of Chemotherapy in NSCLC 1164
Topoisomerase I Inhibitors
1192
Microsatellite alterations
1142
Telomerase
1142
Single-agent chemotherapy
1164
1143
Combination chemotherapy
1164
Decitabine
1193
High-dose chemotherapy
1166
FMdC
1193
STAGING
2
VOLUME 5, NUMBER 1-12 INDEX
Revisions in the International
System for Staging Lung Cancer
1143
Noninvasive Imaging
1143
Novel Chemotherapeutics Approved
for the Treatment of NSCLC
1166
BIOLOGIC AGENTS
Nucleosides
Platinum-based Agents
1193
1202
Nedaplatin
1202
1166
CT staging
1143
Oxaliplatin
1203
FDG PET imaging
1143
Interleukin 2 (IL-2)
1166
1203
MR scanning
1144
Interferon β (IFN-β)
Satraplatin
1166
Other Agents
1203
Surgical Staging
1144
MULTIMODALITY THERAPY
1167
Bendamustin
1203
Adjuvant Chemotherapy
1167
CHS 828
1203
Chemoradiotherapy
1168
CI-994
1204
Irofulven
1204
Temozolomide
1204
Tirapazamine
1204
Mediastinotomy/
mediastinoscopy
1144
Thoracoscopy and video-assisted
thoracoscopy (VATS)
1144
Intra-operative sentinel lymph
node mapping
Molecular Substaging
PROGNOSIS
Serum Markers
Tissue Pathology
Angiogenesis evaluation
1144
1145
1146
1146
1147
1147
Genetic Tests
1147
FDG PET Imaging
1148
LUNG CANCER — PART V
NON-SMALL-CELL LUNG CANCERCURRENT MANAGEMENT STRATEGIES
EPIDEMIOLOGY BY AGE AND STAGE
IN THE USA
1150
Incidence of NSCLC by Gender
and Age
1150
Incidence of NSCLC by Stage
1150
First-year and Five-year
Survival by Stage
Treatment Approaches by Stage
SURGERY
1150
1150
1150
Neoadjuvant/Induction Chemotherapy
and Trimodality Therapy
1168
OTHER TREATMENT MODALITIES
1181
Laser Ablation
1181
Photodynamic Therapy (PDT)
1181
NOVEL FORMULATIONS
AND DRUG DELIVERY APPROACHES
1205
Photofrin
1182
LumaCare LC-051
1183
Onco TCS
1205
PH-10
1183
Liposome-encapsulated
paclitaxel
1205
Hyperthermia
1183
Lipid Formulations
Aerosol Delivery
1205
1205
BSD-2000/3D System
1184
Perfusion-induced systemic
hyperthermia (PISH)
Aerosol doxorubicin
1206
1184
Aerosol retinoids
1206
1184
Aerosolized GM-CSF
1206
Inhaled RFS 2000
1206
Cryotherapy
Radiofrequency bronchoscopic
surgery with cryotherapy
Stents
1184
1185
Silicone stents
1185
Expandable metallic stents
1185
LUNG CANCER — PART VI
NOVEL AGENTS/FORMULATIONS
IN DEVELOPMENT
NOVEL CHEMOTHERAPEUTICS
1190
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
ANGIOGENESIS INHIBITORS
Matrix Metalloproteinase
Inhibitors (MMPI)
1206
1206
BMS-275291
1207
Marimastat
1207
Neovastat
1207
Prinomastat
1208
Angiostatin and Endostatin
1208
Squalamine
1208
FUTURE ONCOLOGY
VEGF Antagonists
VOLUME 5, NUMBER 1-12 INDEX
1208
Angiozyme
1208
rhuMAb-VEGF
1209
Pantacea
Radiosensitizers
KIN-806
SEPTEMBER 2000
1219
Telomerase
1261
1219
1219
p53 mutations and other
genetic markers
1262
1264
1266
Semoxind
1209
Motexafin gadolinium
1219
Cytokeratin (CK)
Other Agents
1209
RSR-13
1220
BN-50730
1209
Hyaluronic acid (HA) and
hyaluronidase (HAase)
REGULATION
Cell Cycle Regulation
1209
Proton Beam Therapy
CHEMOPREVENTION
1220
1221
Cystoscopy/Biopsy
1266
HISTOPATHOLOGY AND BLADDER CANCER
TYPES
1267
1209
Vitamins
1221
Flavopiridol
1209
UCN-01
1210
Nonsteroidal Anti-inflammatory
(NSAI) Drugs/Derivatives
1221
Transitional Cell Carcinoma
(TCC)
1267
Celecoxib
1221
Squamous Cell Carcinoma
1267
Exisulind
1221
Adenocarcinoma
1267
Approaches Targeting the Epidermal
Growth Factor Receptor (EGFr)
1210
ABX-EGF
1210
Retinoids
1222
Trastuzumab
1210
Thymalfasin
1223
ZD 1839
1211
Farnesyl Tranferase Inhibitors
(FTI)
1211
R11577
1211
SCH 66336
1211
Approaches Targeting p53
1211
rAd/p53
1211
RPR/INGN 201
1212
ONYX-015
Agents Targeting Other Markers
G3139
ISIS 3521
IMMUNOTHERAPY/VACCINES
1227
1212
1213
1213
1214
1214
Dendritic cells expressing CEA 1216
1216
1217
1217
Vaccines Against MUC-1-expressing
Tumors
1217
BLP-25
1217
1218
HER2 Peptide Vaccine
1218
Radioimmunoconjugates
PATHOGENESIS
EPIDEMIOLOGY
1228
1228
Global Incidence and Mortality
1228
USA Incidence
1228
1219
1219
UPDATE ON TAXANES
1025
Taxol
1025
Taxotere
1026
CLINICAL INDICATIONS
1026
Ovarian Cancer
1026
Breast Cancer
1027
Lung Cancer
1028
Other Cancer Indications
1028
THE OUTLOOK FOR TAXOL AND
ITS COMPETITION
1028
Taxane Sources and
Production Processes
Gender
1228
Age
1229
Aphios
1029
1229
Cytoclonal Pharmaceutics
1029
1229
Dabur India
1029
NaPro BioTherapeutics
1029
Phytogen Life Sciences
1029
Phyton
1030
Samyang Genex
1030
Xechem International
1030
USA Prevalence
TUMOR MARKERS
BLADDER CANCER — PART II
SCREENING, DIAGNOSIS, STAGING
AND FOLLOW-UP
SCREENING
1250
DIAGNOSIS AND FOLLOW-UP
1253
In Vitro Testing Approaches
Generic Paclitaxel
1028
1030
1253
Faulding
1030
1255
IVAX/Immunex
1031
ImmunoCyt
1255
Mylan Pharmaceuticals
1032
Quanticyt
1255
Sicor
1032
1256
SuperGen
1032
Yew Tree Pharmaceuticals
1032
Urine cytology/cytopathology
Bladder tumor antigen (BTA)
Nuclear matrix proteins (NMP) 1258
Vaccines Against Tumors
Expressing HER2
RADIATION THERAPY
1226
Health Factors
Recombinant viruses expressing
CEA protein or peptides
1214
Mitumomab (BEC2)
Environmental and Occupational
Exposure
1212
1213
Fucosyl-GM1-keyhole limpet
hemocyanin (KLH) conjugate
vaccine
1225
1227
SRL172
Vaccines Against Gangliosideexpressing Tumors
Tobacco Smoking
Lifestyle Factors
1213
Anti-CEA antibodies
1225
1267
ANTICANCER DRUGS AND MARKETS
COMMERCIAL PRODUCTS
ETIOLOGY
1212
Cytokine-producing Tumor
Vaccines
Vaccines Against CEA-expressing
Tumors
BLADDER CANCER — PART I
ETIOLOGY, EPIDEMIOLOGY AND
TUMOR MARKERS
STAGE AND GRADE
NMP-22
1258
BCLA-4
1260
Abbott Laboratories
1032
1261
Baker Norton
Pharmaceuticals/Ivax
1032
Fibrin/fibrinogen degradation
products (FDP)
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
Novel Formulations
1032
3
FUTURE ONCOLOGY
SEPTEMBER 2000
Cell Therapeutics
1033
Mixed-backbone ODN (MBO)
1233
EnzyMed
1033
Morpholino ODN
1236
1033
Peptide nucleic acid (PNA)
linkage ODN
1236
Locked nucleic acid (LNA)
ODN
1237
Guilford Pharmaceutical
MacroMed
1033
Matrix Pharmaceutical
1034
NeoPharm
1034
Phytogen Life Sciences
1034
Delivery Strategies and
Entry into Cells
1237
Pharmacia & Upjohn
1034
Virus-mediated transfer
Protarga
1034
Attachment of lipophilic groups 1238
SuperGen
1035
Fusogenic peptides
1238
1237
STS Particles/Medisperse
1035
Phenoxazine-modified ODN
1238
Xechem International
1035
Streptolysin O
1239
1036
Electroporation
1239
Aventis
1036
Microinjection
1239
Bristol-Myers Squibb
1036
Scrape-loading
1239
Novel Taxanes and Analogs
ODN Conjugated to Radioisotopes 1278
CLINICAL CONSIDERATIONS
1278
Toxicity
1278
Administration Route
1278
Oral delivery
1278
Pulmonary delivery
1279
Combination Therapy
1279
Starburst polyamidoamine
(PAMAM) dendrimers
1241
Copolymers
1245
Amphiphiles
1245
Porphyrins
1246
Carrier-ligand conjugates
1246
Controlled-released carriers
1247
Virosomes
1247
British Technology Group (BTG) 1036
Osmotic-loading or osmotic-lysis 1239
Indena
1036
Syringe-medicated loading
1239
The Lipsome Company (TLC)
1037
Hormone carriers
1239
Taxolog
1037
Spherulites
1240
ONCOLOGY TRENDS
PRODUCT MARKETS — PART I
Xechem International
1037
Cationic lipid facilitators
(lipids and liposomes)
1240
PLATINUM-BASED ANTICANCER AGENTS 1046
Next Generation of Tubulin
Stabilizing Drugs/Spindle Poisons
4
VOLUME 5, NUMBER 1-12 INDEX
SPECIAL REVIEW
1037
Cisplatin
1046
Apramycin
1037
Carboplatin
1047
D-24851
1037
Oxaliplatin
1047
Discodermolide
1038
Eleutherobin
1038
Epothilones
1038
Halimide
1038
LY355703
1038
SYNTHETIC NUCLEIC ACID
SEQUENCE CONSTRUCTS
AS ONCOLOGY
THERAPEUTICS — PART II
TYPES OF SYNTHETIC NUCLEIC ACID
CONSTRUCTS IN DEVELOPMENT
AS ONCOLOGY THERAPEUTICS
1269
Antisense Oligos
1269
Laulimalide and isolaulimalide 1039
Triplex-Forming ODN (TFO)
1269
T138067
Catalytic Nucleic Acids/Ribozymes 1270
1039
Hammerhead ribozymes
TECHNOLOGY UPDATE
SYNTHETIC NUCLEIC ACID
SEQUENCE-SPECIFIC
CONSTRUCTS AS ONCOLOGY
THERAPEUTICS — PART I
MECHANISM OF ACTION
1229
DESIRABLE ATTRIBUTES OF
SYNTHETIC NUCLEIC ACID SEQUENCES
AS THERAPEUTICS
1230
Sequence Structure and Length
1230
1271
Minizyme
1271
Maxizymes
1271
Hairpin ribozymes
1271
Snorbozymes
1272
Deoxyribozymes or DNA enzymes
(DNAzymes)
1272
Dy-Tex ribozyme analogs
Chimeric Nucleotides
1272
1272
Intracellularly Produced Antisense
RNA and DNA
1273
TOPOISOMERASE I INHIBITORS
1048
Topotecan
1049
Irinotecan
1050
THYMIDYLATE SYNTHASE INHIBITORS/
ANTIFOLATES AND RELATED AGENTS
1050
Capecitabine
1051
Raltitrexed
1051
UFT
1051
ONCOLOGY TRENDS
PRODUCT MARKETS — PART II
HORMONE MODULATING DRUGS
1084
Antiestrogens
1085
Tamoxifene
1085
Raloxifene
1085
Toremifene
1086
Aromatase Inhibitors
1086
Anastozole
1087
1274
Exemestane
1088
1230
Aptazymes
1275
Fadrozole
1088
1230
Aptamers as diagnostics
1276
Formestane
1089
Methylphosphonate (M=P) ODN 1231
BIOLOGICAL ACTIVITY OF ODN
Backbone Modifications and
Consequences
Phosphorothioate (P=S) ODN
N3’-P5’ phosphoramidate
(P=A) ODN
1232
Aptamers
1276
Letrozole
1089
CpG-containing ODN
1276
Antiandrogens
1089
G-rich ODN
1277
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
Bicalutamide
1090
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
SEPTEMBER 2000
Cyproterone acetate
1090
Interferon α-2a
1099
Flutamide
1090
Interferon α-2b
1099
Goserelin
1090
Rituximab
1099
Leuprolide acetate
1091
Trastuzumab
1101
Nilutamide
1091
ADJUNCT THERAPIES
1101
1091
Amifostine
1101
Alitretinoin
1091
Colony Stimulating Factors
1102
Anthracyclines
1092
Filgrastim
1102
Daunorubicin
1092
Lenograstim
1102
Epirubicin
1092
Sargramostim
1102
Liposomal daunorubicin
1092
Octreotide Acetate
1103
Liposomal doxorubicin
1092
Oprelvekin
1103
Mitoxantrone
1094
Pamidronate Disodium
Valrubicin
1094
OTHER CHEMOTHERAPEUTICS
Busulfan
1094
Carmustine Wafer
1094
Etoposide Phosphate
1095
Flutarabine
1095
Gemcitabine
1095
Liposomal Cytarabine
1095
Methoxsalen
1096
Porfimer Sodium
1096
Temozolomide
BIOLOGICALS
1096
1098
Aldesleukin
1098
Denileukin Diftitox
1098
Interferon α
1099
1104
MEETING COVERAGE
CHEMOTHERAPY IN NON-SMALL
CELL LUNG CANCER (NSCLC)
FROM THE 35TH ANNUAL MEETING
OF THE AMERICAN SOCIETY OF CLINICAL
ONCOLOGY, ATLANTA, GA;
MAY 15-18, 1999
APPROACHES TO MAXIMIZE THE ROLE
OF CHEMOTHERAPY IN NSCLC
Postoperative Adjunct
Chemotherapy
in Resected Disease
Neoadjuvant Chemotherapy
in Resectable Disease
1052
Neoadjuvant Chemoradiotherapy
in Resectable Disease
1058
Induction Chemotherapy and
Concomitant Chemoradiotherapy
in Unresectable Stage III Disease 1059
Concurrent Versus Sequential
Chemoradiotherapy in
Unresectable Disease
1060
Postoperative Chemotherapy
with or without Radiotherapy
in Resected Disease
1060
COMMERCIALLY AVAILABLE
CHEMOTHERAPEUTICS IN CLINICAL
TRIALS IN ADVANCED DISEASE
1061
Two-drug Combination/
Multimodality Therapies
1061
Platinum-based
chemotherapy regimens
1061
Taxane-based combinations
1066
Other combinations
1066
Monochemotherapies
1067
Docetaxel
1067
Paclitaxel
1069
Vinorelbine
1070
Irinotecan
1070
Multidrug Regimens in
Advanced Disease
1070
5
1053
Three-drug platinumcontaining regimens
1070
1053
A dose-intensive 4-drug
combination
1071
LIST OF EXHIBITS
TITLE
Historic and Forecast Taxane
Sales in the USA and Abroad
PAGE
XXXX
Estimated Cases under Treatment
with Taxol and Taxotere Worldwide
(1997-1999)
XXXX
Competitive Strategies in
the Paclitaxel Market
Estimated Incidence of Lung
Cancer Around the World by
Gender in 1999
Estimated Mortality of Lung
Cancer Around the World by
Gender in 1999
XXXX
1043
TITLE
PAGE
Global Sales of Selected Anticancer
Drugs and Related Products
1054
Select Platinum-based Drugs
in Development
1057
Selected Topoisomerase I (Topo I)
Inhibitors in Development
1062
Selected Thymidylate Synthase
Inhibitors and Related Agents in
Development
1068
Estimated Number of Smokers over
18 Years-of-Age in the USA in 1999
by Gender and Age
1076
Lung Cancer Incidence in Europe
by Country and Gender in 1999
1047
Estimated Number of Smokers by
Average Cigarettes Smoked per Day
in the USA in 1999 by Gender
and Age
1079
Lung Cancer Deaths by Gender
in Europe by Country in 1999
1048
Projects Funded by the NCI Early
Detection Research Network
1081
Lung Cancer Incidence and Deaths
in the Triad in 1999
1053
Epidemiology of Lung Cancer in
the USA by Type in 1999
1087
1044
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
TITLE
PAGE
Antiestrogen Drugs in Development
Adverse Cardiac Events
with Herceptin
Incidence and 5-year Survival
Estimates of Patients with Small-Cell
Lung Cancer in the USA
Estimated Incidence of Small-Cell
Lung Cancer in the Triad in 1999
Selected Tumor Markers Associated
with Small-Cell Lung Cancer
Standard treatment Options for
Small-Cell Lung Cancer
Estimated Small-Cell Lung Cancer
Cases by Type of Treatment in the
USA in 1999
Combination and Multimodality
Clinical Trials in Small-cell
Lung Cancer
Histologic Classification of NSCLC
and Estimated Incidence in the USA
in 2000
1097
1102
1107
1109
1110
1115
1117
1119
1132
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
SEPTEMBER 2000
TITLE
PAGE
TITLE
Staging of NSCLC
1134
Biomarkers Associated
with NSCLC
Estimated Mortality of Bladder Cancer
by Age Group in the USA in 2000
1238
1137
Potential Numbers of Chemotherapy
Regimens for the Treatment of Lung
Cancer
1192
1242
1151
Selected Agents in Development for
the Treatment of Lung Cancer
1194
Estimated Incidence of NSCLC
by Gender and Age
Phase II and III Combination
and Multimodality Clinical Trials
in NSCLC
In Vitro Tests for the Screening,
Diagnosis, and Monitoring of Bladder
Cancer
1251
Comparison of BTA Stat and Cytology
in Bladder Cancer Monitoring
1258
Comparisons of UBC, BTA
and NMP-22 Tests
1268
Incidence of Bladder Cancer by
Histologic Type in the USA in 2000
1271
Estimated Bladder Cancer Mortality
in Europe by Country and Gender
in 2000
1235
Basis for Staging of Bladder Cancer
1273
Incidence of Bladder Cancer by
Stage in the USA in 2000
1275
Estimated Incidence of Bladder Cancer
by Age Group in the USA in 2000
1236
Incidence of Bladder Cancer by
Grade in the USA in 2000
1277
Estimated Bladder Cancer Incidence
in Europe by Country and Gender
in 2000
1234
1157
Novel Chemotherapeutics Approved
in the USA for the Treatment
of NSCLC
1159
1169
PAGE
Markers Associated with
Bladder Cancer
Estimated Mortality of Bladder
Cancer Around the World by Region
and Gender in 2000
1232
1154
Treatment Options and Prognosis
by Stage
TITLE
Estimated Incidence of Bladder
Cancer Around the World by Region
and Gender in 2000
1231
Estimated Stage Distribution at
Diagnosis and 1-year and 5-year
Survival of NSCLC Patients by Stage
in the USA in 2000
1153
First-line Treatment of NSCLC
by Stage in 2000
PAGE
INDEX OF COMPANIES & INSTITUTIONS
12 de Octubre Hospital
1123
Abbott Laboratories
1029, 1032, 1080, 1089,
1091, 1194, 1199, 1200, 1201
6
Abgenix
1194, 1210
Ambion
1252
AMDL
1136
American Home Products
(AHP)
1031, 1055, 1097, 1194
Berlex Laboratories
Auckland Hospital
1123
AVAX Technologies
1062
Betticher Institute of
Medical Oncology
1123
BICO
1184
BioChem Pharma
1195
Biocontrol Technology
1184
BioInvent International
1194
Amgen
1055, 1089, 1090, 1102, 1120
Aventis
1025, 1026,
1036, 1037, 1049, 1118, 1054,
1055, 1160, 1091, 1095, 1102,
1194, 1197, 1198, 1209, 1222
AccuMed International 1078, 1079
Amgen-Kirin
1055, 1102
Aventis Pasteur
1201, 1215
Addenbrookes NHS Trust
1264
Amrad
1102
AVI BioPharma
1236
ADL (Germany)
1259
AnorMED
1057, 1194
Axcan Pharma
Advanced Bioscience Lab
1081
Amos Cancer Center
1120
Ansan
1201
Anthra Pharmaceuticals
1094
Baker Norton
Parmaceuticals
Antigenics
1024
Banyu
1062
Antisoma
1194
Bard Diagnostic Sciences
1257
Barnes-Jewish Hospital
1083
Bar-Ilan Research and
Development
1201
Academisch Ziekenhuis der
Vrije Universiteit
1119
Access Pharmaceuticals
1057
Aeterna Laboratories
1194, 1207
Agouron Pharmaceuticals
1068, 1069, 1194, 1208
Akademiska Hospital
Akorn
Albert Einstein
Cancer Center
1146
1183
1166, 1215
American Pharmaceutical
Partners (APP)
Auckland Cancer Research
Laboratory
1063, 1193, 1202
Aphios
1046
1029
Aquila Biopharmaceuticals
1200, 1217
1194
Alza 1032, 1054, 1055, 1057, 1089,
1092, 1101, 1123, 1159, 1241
1195
biosyn
1167
Bio-Technology General
1029
Boehringer Ingelheim
1031, 1200
Boston Scientific
1185
Brandford University
1097
Arthur G. James Cancer
Hospital & Richard J. Solove
Research Institute
1206, 1220
AltaRex
BioStratum
1259
1247
1094
1252, 1257
BioNumerik Pharmaceuticals
1062, 1068, 1195
Boston Medical Center
Alkermes
Almirall Prodesfarma
1251
Bion Diagnostic
Sciences
Battelle Pulmonary
Therapeutics
Aronex Pharmaceuticals 1057, 1194
1194, 1220
Biomoda
Barr Laboratories 1054, 1083, 1085
1253
Allos Therapeutics
1195, 1217
1245
Alcoa
1034
1062
Biomira
Boehringer Mannheim
1055, 1057, 1109
Armand-Frappier Institute
1052, 1156
1031, 1032
1165
1082
1272
Allegheny University
1184
Biomeasure
1054, 1095
Arcturus Engineering
Albert Einstein College
of Medicine
Allegheny General
Hospital
1162
Azienda Ospedaliera San
Luigi Gonzaga
Bethany Medical Center
Asahi Chemical Industry
1142
Bayer
1194, 1206
1081, 1096, 1206, 1252
Bayer Diagnostics
1141
Baylor College of Medicine
1206, 1253, 1274
Asta Medica
1037, 1046, 1118, 1200, 1211
Beaufour Ipsen
1194, 1209
AstraZeneca
1051,
1054, 1055, 1057, 1068, 1085,
1087, 1088, 1090, 1097, 1193, 1194
Beckman Coulter
1197, 1219
Bedford Laboratories
1046, 1092
Atairgin Technologies
1081
Beijing Tumor Institute
Beki Diagnostics
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
1259
1109, 1252
Brigham and Women’s
Hospital
1145, 1181, 1247
Bristol-Myers Squibb (BMS)
1025, 1026,
1027, 1028, 1029, 1030, 1032, 1036,
1037, 1038, 1046, 1047, 1051, 1054,
1057, 1093,1095, 1101, 1117, 1118,
1122, 1161,1163, 1191, 1192, 1193,
1195, 1196, 1200, 1201, 1203, 1207
FUTURE ONCOLOGY
British Biotech
VOLUME 5, NUMBER 1-12 INDEX
1195, 1197, 1207
British Columbia
Cancer Agency
1162, 1241
British Technology Group
(BTG)
1036, 1062
Brooke Army Medical Center 1033
Clatterbridge Centre
for Oncology
1124
Clayton Foundation for
Research
1201
Cleveland Clinic Foundation
1186, 1208, 1254, 1259
1185
ClinSites
1033
Bryn Mawr College
1200
COBE BCT
1081
BSD Medical
1184
Codon Pharmaceuticals
1270
Burnham Institute
1197
Columbia University
1246
1142
Community Hospital of
Hamburg
Bryan
Cancer Diagnostics
Cancer Research Campaign
1033, 1057, 1192, 1193, 1194,
1198, 1202, 1204, 1252, 1264
Cancer Research Center
of Hawaii
1039
1199
Genelabs Biotechnology
1197
Eastern Virginia Medical
School
1082, 1250
Genentech
1026, 1027, 1054,
1099, 1101, 1197, 1209, 1210
Eichrom Technologies
1242, 1252, 1261
General Biologicals
Eli Lilly
1038, 1047, 1048, 1054, 1068,
1085, 1086, 1095, 1097, 1159,
1161, 1193, 1196, 1201, 1222
Ellis Fischel Cancer Center
1132
1097
Enzon
1099, 1196
1082, 1196, 1218
1257
Cornell University
1030, 1172, 1217
Coulter Pharmaceutical
Cell Genesys
Cross Cancer Center
Cell Therapeutics (CTI)
1033, 1062, 1192, 1195, 1196
Gem Pharmaceuticals
1196, 1208
Cedars-Sinai Medical Center 1180
1195, 1221, 1222
Eastern Cooperative Oncology
Group (ECOG)
1162, 1211, 1212
EntreMed
C. R. Bard
Cell Pathways
1197
Endorecherche
Corixa
1195, 1196
1077
GelTex Pharmaceuticals
1097
1185
1022
1058
GE Medical Systems
Duramed Pharmaceuticals
Cordis
1101
Catholic University
Galena
1185
Cangene
1195, 1211
1172
DuPont Pharmaceuticals
1097, 1113, 1114
Cook
Cancer Therapeutics
Canji
1122
Consultants in Blood
Disorders and Cancer
SEPTEMBER 2000
Cyclex
1100
1136, 1218
1035, 1057, 1201
CytImmune Sciences
1196
1031
1259
General Hospital of
Bolzano (Italy)
1266
GeneSense Technologies
1197
Genetica
1081
Genetics Institute
1102
Genetix Pharmaceuticals
1197
Genetronics Biomedical
1239
Gensia Sicor
1032
Genta
1236, 1197, 1212
EnzyMed
1033
EORTC
1267
Genzyme Molecular
Oncology
EpiGenesis
1279
G. Gaslini Children’s Hospital 1241
Esteve
1200
Georg-August-University
1140, 1195
1113
Europe Organization for the
Research and Treatment of Cancer
(EORTC)
1161, 1163, 1171,
1203, 1204, 1206, 1207, 1217
Georgetown University
1034, 1199, 1216
Exiqon
Gesellshaft für Biotechnologische
Forschung
1038
Geron
1252, 1261
Cellcor
1023
Cytoclonal Pharmaceutics
(CPI)
1029, 1196
Celltech Group
1207
Cytogen
1023
Faulding
CytoGenix
1274
Feist-Weiller Cancer Center
Cytoskeleton
1037
Ferrer Internacional
Cytyc
1079
Ferring
1030
Glaxo Wellcome
1054, 1055, 1062, 1068, 1275
Cytovia
1195
Finnish Institute of
Occupational Health
1130
Glaxo SmithKline
1163, 1196, 1197, 1198, 1218
1259
Glycosyn Pharmaceuticals
1062
1201
Centers for Disease Control
and Prevention (CDC)
Centre de Recherches de
Biochimie Macromoleculaire
Centre Hospitalier
Intercommunal
Centre of Molecular
Immunology (CIM)
Centre Pluridisciplinaire
d’Oncologie
1042
1245
1029
1263
1098, 1099
Gilead Sciences
1062, 1092, 1238, 1274, 1275
Dabur India
Fisher Diagnostics
1202
Daiichi Pharmaceutical
1062, 1192, 1196
Fisher Scientific
1259
Goodwin Biotechnology
Daikin Industries
Fletcher International
1195
Gothenburg University 1059, 1170
1196, 1219
Food and Drug Administration
(FDA)
1255, 1256, 1258, 1259
Grant Laser Center
1182
Graves Gilbert Clinic
1172
Dana-Farber Cancer Institute
1069, 1195, 1196, 1210
Florida State University (FSU) 1037
Greenlane Hospital
1123
Fordham University
1024
Gregorio Marañón Hospital
1123
Dartmouth Medical
1198
Grelan Pharmaceutical
1195
David Bull Labs
1030
Foundation for
Blood Research
1133
David Grant Medical Center
1120
Davis Cancer Center
1120
Dendritech
1244
Dainippon Pharmaceutical
1199
Centocor
1054
Dako
1255
Chiba University
1178
Children’s Hospital, Boston
1196, 1197
1029
Chiron
1054,
1095, 1098, 1166, 1196, 1200
ChromaVision
Medical Systems
1029, 1030, 1255
1203
1123
ChiRex
1237
1251
Chugai Pharmaceutical
1046, 1055, 1095, 1098
DepoTech
1095, 1096
DiagnoCure
1251, 1253, 1255
Fox Chase Cancer
Center
1205, 1209, 1215
Fred Hutchinson Cancer
Research Center
1218
Free University Hospital
(The Netherlands)
1162
1247
Guilford Pharmaceuticals
1033, 1054, 1094, 1095
Hadassah Medical Center
(Israel)
1257
Harbor Branch Oceanographic
Institution (HBOI)
1038
Harefield Hospital
1184
Harvard School of
Public Health
1130
Ci-Tec
1183
Diatide
1112
Frei-Universitat Berlin
CIBA Vision
1229
Dow Corning
1241
Ciphergen Biosystems
1082, 1250, 1252
Draxis Health
1032
Freie Universitat Berlin
(Germany)
1256, 1266
Drug Royalty
1029, 1030
Fujirebio
1136, 1251
Harvard University
Medical School 1196, 1197, 1247
Circon
Duke University Medical
Center
1082, 1097,
1144, 1145, 1153, 1176, 1216
Fujisawa
1046, 1196
Hauser
1196, 1198
Helsinki University
Central Hospital
City of Hope National
Medical Center
1081
1272
Galderma Research &
Development
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
1029, 1031, 1032
1175, 1177
7
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
HemoCleanse
1184
Herbert Irving Comprehensive
Cancer Center
1166
Hoag Cancer Center
1199
Hoffmann-La Roche
1050, 1054, 1055, 1057, 1069,
1089, 1099, 1101, 1102, 1194, 1197
Hood Laboratories
1185
Hôpital Arnaud de Villeneuve 1119
1198
Karolinska Institute
Indena
1036
Kay Kendall Leukaemia Fund 1198
Indiana University
1089, 1173, 1174
Inex Pharmaceuticals
1062, 1198
InNova
1029
Innovir Laboratories
1241
Inselspital
1171
INSERM
1130, 1240
1237
Kellogg Cancer Center
1144
Kent Cancer Centre
1214
Kimeragen
1273
Kinki University School
of Medicine
1171
Klinge Pharma
1097, 1102, 1200, 1203
Klinge Pharmaceuticals
1097
1036
Klinikum Grosshadern
(Germany)
1135, 1184
1062
Kliniken Ibbenbüren
1120
Konica
1259
Hospital Duran i Reynals
1113, 1114, 1173
Institute for Drug Development,
Cancer Therapy and Research
Center
1036
Hospital Großhansdorf
1122
Institute of Biostructure
Hospital Gauting
1122
Institut de Genetique
Moleculaire de Montpellier
1238
Hospital Arnaud de Vilanova 1179
Institut Curie
Hospital de Cruces
1173
Institut Henri Beaufour
Hospital del Mar
1180
Hôpital Ste-Marguerite
1121
Hospital General Universitario
de Alicante (Spain)
1265
Hospital Vall d’Hebron
8
Incyte Genomics
1024, 1157
Hoechst Celanese
SEPTEMBER 2000
1101
Kosan Biosiences
1038
KS Biomedix
1214
Institute of Cancer Research 1198
Kurume University School
of Medicine
1178
Institute of Pathology, Berlin
Kymed
1097
1183
1135
International Agency for
Research on Cancer
1130, 1227
1099
IDEC Pharmaceuticals
1049, 1054, 1099, 1100
IDL Biotech
IDT
IGT Pharma
1146, 1251, 1265
1184
1191, 1197
Ilex Oncology
1063, 1068, 1196, 1197, 1207
Imatron
1135
ImClone Systems
1197, 1217
Immune Response
1246
Immunex
1025, 1031, 1032, 1054, 1055,
1094, 1103, 1194, 1201, 1210
Immuno-Designed Molecules
(IDM)
1199
ImmunoGen
Immunomedics
Immunotech
1191, 1197, 1198
1197, 1219
1219
1254
MBG Technologies
1183
M. D. Anderson
Cancer Center (MDACC)
1024, 1033, 1035, 1057,
1062, 1137, 1139, 1082, 1194,
1195, 1198, 1202, 1206, 1207, 1208,
1209, 1211, 1212, 1240, 1250, 1259
MDS Research Foundation
1037
Medarex
1199
1094
1168
Medical Research Council
(MRC)
Isis Pharmaceuticals
1198, 1213, 1233, 1236, 1246
ICN Pharmaceuticals
Mayo Graduate School
of Medicine
1032
1259
1197, 1219
1045, 1074, 1102, 1157,
1160, 1183, 1206, 1209, 1211
Leo Pharmaceutical
Products
1233
IBC Pharmaceuticals
1195
Mayo Clinic
Lemery
Hybritech
1138, 1197
Maxim Pharmaceuticals
ISIS Innovation
Hybridon
Hyseq
1198
Introgen Therapeutics 1198, 1212
1271
1089
Maxia Pharmaceuticals
1030
Humbobolt-Universitat zu
Berlin
1174
1243, 1252, 1258, 1259
Matrix Pharmaceutical
1034, 1057, 1062, 1193, 1198
Lachema
1136
Hygeia Hospital
Matritech
Medeva
Hubei Medical University
Hydro Med Sciences
Kyowa Hakko Kogyo
1068, 1198, 1200, 1210
Massachusetts Institute
of Technology
1033, 1181, 1246, 1252, 1259
Intracel
1252
1057
Istituto Nazionale per la
Ricerca sul Cancro
1213
MedImmune Oncology
1159
Leukaemia Research Fund
1198
Medisperse
1035
Lexigen Pharmaceuticals
1198
Memorial-Sloan Kettering
Cancer Center 1074, 1172, 1176,
1197, 1199, 1200, 1206, 1217
1198, 1203
Lexon
1142, 1252
Istituto Nazionale per lo Studio
e la Cura dei Tumori
1164
Ligand Pharmaceuticals
1091, 1092, 1097, 1098
Istituto Nazionale Tumori
1142, 1179
The Liposome Company
1037, 1055, 1093
Mentor
Ivax
1029, 1031, 1032
Lithuanian Oncology Center 1167
1088
Loma Linda University
Medical Center
1156, 1220
Merck KGaA
1197, 1199, 1217, 1256
Janssen
Janssen Biotech
1035, 1057, 1201
Janssen Pharmaceutica
Japan Tobacco
1198
1194, 1195
Johann Wolfgang
Goethe Universitat
1245
Johns Hopkins University
1033, 1034,
1074, 1081, 1192, 1195, 1197
Johnson & Johnson
1054, 1055, 1185, 1211
Johnson & Johnson Research 1239
Johnson Matthey
1057, 1203
Jonsson Comprehensive
Cancer Center
1210
Josai University
1269
Kagoshima University
1069
Imperial Cancer
Research Fund (ICRF)
1062, 1194, 1195, 1199, 1201
Kaiser Permanente
Kaplan Cancer Center
Imperial Cancer Research
Technology (ICRT)
1199, 1201
Karmanos Cancer Institute
Karo Bio
1097
1209, 1228
Lombardi Cancer Center
1081
Louisiana Oncology
Associates
1172
Menssana Research
1079
1252, 1261
Merck
1062, 1097, 1221
Metaxas Memorial Cancer
Hospital
1159, 1180
MGI Pharma
1055, 1199, 1204
Michigan Molecular Institute
1244
Microvasive
1185
Louisiana State University
Health Sciences Center
1263
Lucca Hospital
1173
Middlesex Hospital-Meyerstein
Institute
1119
Ludwig-Maximilians
University
1135
Miravant Medical
Technologies
1182
LumaCare
1183
Moffitt Cancer Center
1141
Lungenklinik
1155
Montana State University
1029
Lynx Therapeutics
1233
MacroMed
1030, 1033
Mallinckrodt
1112
Magainin Pharmaceuticals
1198, 1208
Marie Lannelongue Hospital
1151
1211
Martek Biosciences
1200
1141
Massachusetts General
Hospital
1181, 1246, 1259, 1275
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
Mount Sinai Comprehensive
Cancer Center
1176
Mount Sinai School of
Medicine
1024, 1082
MPI Research
1068
Munich University
Medical School
1184
Mylan Pharmaceutical
1029, 1032, 1085
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
Myriad Genetics
1199
Nexagen
Nanodesign
1097
Nexell Therapeutics
NaPro BioTherapeutics
1029, 1030, 1031, 1032
National Cancer Center
Hospital East
1157, 1174
National Cancer
Center Hospital
1120
1275
1142, 1241
NeXstar Pharmaceuticals
1030, 1054, 1055, 1062, 1275
National Cancer Institute
(Italy)
1240
National Cancer Institute
of Canada
1125, 1207
National Center for Health
Statistics (NCHS)
National Hospital
(Republic of South Africa)
National Human Genome
Research Institute (NHGRI)
1042
1177
1263
1094, 1195, 1257
Palmerston North Hospital
1123
Panum Institute
1236
Parke-Davis
1197
Nordic Drugs
1030
Peptech
1199
Northwest Biotherapeutics
1199
PerImmune
1261
1097, 1197, 1199, 1204
Pfizer
1097, 1194, 1199, 1202, 1208
Norton Healthcare
1031
Novalon Pharmaceutical
1097
Pharmachemie
1032, 1046, 1085, 1201
Norvartis
1032, 1054, 1055, 1087, 1088,
1089, 1103, 1112, 1198, 1229
Novartis Horsham
Research Centre
Pharmacia
1191, 1198, 1199, 1205, 1221
Pharmacia & Upjohn 1034, 1049,
1054, 1062, 1088, 1092, 1118
1279
Pharmacyclics
Novartis Pharma KK
1103
PharmaGenix
Novo Nordisk
1097
PharmaMar
Novocastra Laboratories
1263
Phillips Petroleun
1253
Novogen
1097
Photogen Technologies
1183
Novopharm Biotech
1202
Phytogen Life Science
1029, 1030, 1032, 1034
Nycomed Amersham
1032, 1054, 1112, 1113, 1199
Robert H. Lurie Comprehensive
Cancer Center
1081, 1168
Robert Wood Johnson (RWJ)
Medical School
1182, 1199, 1272
1274
1063, 1199
Pierre Fabré Medicament
1086, 1089
Roche Diagnostics
1108, 1109,
1136, 1250, 1251, 1252, 1264
Rotterdam Cancer Institute
Royal Brompton Hospital
1158
Royal Marsden Hospital
1214
Rüsch
1185
Rush-Presbyterian
St. Luke’s Medical Center
1174
Russian Academy of Medical
Sciences
1135
Rutgers University
1062
1094
Saiseikai Central Hospital
1152
1200
Nycomed Pharma
1094
Pierre Fabre Oncologie
1063
Sakai Chemical Industry
Ohio State University
1220
Policlinico Hospital
1181
Samyang Genex
National Institute for Occupational
Safety and Health (NIOSH)
1227
Oncology St. Gallen
1123
Praecis Pharmaceuticals
1089
San Antonio Cancer
Institute
Oncometrics
1078
1201
Sangtec Medical
National Institute of Dental
and Craniofacial Research
(NIDCR)
Princeton University
Oncor
1270
Professional Compounding
Centers of America
1274
Onyx Pharmaceuticals 1199, 1212
Progen Industries
1200
Optivus
Progenics
Pharmaceuticals
National Kyushu
Cancer Center
1171, 1178
National Naval Medical Center 1133
National Research Council
National Shikoku Cancer
Center Hospital
National Taiwan
University Hospital
1197
1169
Onyvax
1200
1220
ORCA Biosciences
1082
Orebro Medical
Centre Hospital
Organon Teknika
Orion Pharma
Orphan Medical
1181
National University
Hospital/Rigshospitalet
(Denmark)
1179
Nebraska Medical Center
1245
Ortho Biotech,
Janssen-Cilag
1200, 1217
1175
Proligo
1237
1023
Protarga
1023, 1055
1170
1030, 1033
1191
1109, 1251
Sankyo
1097
1094
Osaka Central Hospital
1252, 1257
Prolifix
1054, 1055, 1086
1222
Roy Castle International Centre
for Lung Cancer Research (RCIC)
1136, 1142, 1198
Polymedco
1112
1275
Roswell Park Cancer Institute
1036, 1191
Oncogene Research Products 1081
National Institutes of Health
(NIH)
1022, 1076, 1142, 1263
1269
Roberts Pharmaceutical
Rockefeller University
1081, 1168
1202
National Cancer Institute (NCI)
1022, 1024, 1025, 1035, 1038,
1042, 1045, 1059, 1063, 1068,
1076, 1077, 1078, 1079, 1080, 1082,
1086, 1100, 1101, 1114, 1121, 1123,
1130, 1141, 1152, 1183, 1184, 1194,
1196, 1197, 1198, 1199, 1200, 1201,
1203, 1204, 1205, 1206, 1207, 1211,
1212, 1215, 1216, 1220, 1228, 1270
Paladin Labs
Nippon Kayaku
Northwestern University
National Cancer Center
Hospital
SEPTEMBER 2000
1034, 1192, 1200
QLT Phototherapeutics
1054, 1096, 1162
1055
Sanofi-Synthelabo
1047, 1054,
1163, 1200, 1203, 1204
Santa Creu i Sant Pau
1123
Sapporo City General
Hospital
1180
Sarah Cannon Cancer
Center
1172, 1177, 1192
Schering AG
1054, 1090, 1100, 1167, 1275
Schering-Plough
1054, 1055, 1086, 1090, 1096,
1097, 1098, 1099, 1101, 1159,
1195, 1199, 1200, 1204, 1211
Rajavithi Hospital
1175
Rakepoll Holding
1032
Regina Elena Cancer
Institute
1173
SciClone Pharmaceuticals
Regina Elena Institute for
Cancer Research
1239
Scotia
Pharmaceuticals
1182, 1200
Scripps Institute of
Oceanography
1038, 1198
1222
Osaka University
Medical School
1069
OSI Pharmaceuticals
1199
Ospedale Bellaria-Maggiore
1182
Research Corporation
Technologies (RCT)
1046
Netherlands Cancer Institute
1033, 1034, 1124
Ospedale S. Andrea
1178
Research Genetics
1081
Ospedale San Giovanni
1036
Scripps Research Institute
1038, 1198
Neuromedica
Ospedale Santa Maria
delle Croci
Research Triangle
Pharmaceuticals (RTP)
1035
1147
Seinajoki Central Hospital
(Finland)
NeoPharm
1034, 1199, 1205
NeoRx
1113
1034
New York Hospital/
Cornell Medical Center
1077
New York State University
1034
Otsuka Pharmaceutical
1063, 1068, 1069, 1199
New York University
1063
Oxford Glycosciences
1082
Newcastle General Hospital
1036
Pacific BioTechnologies
1029
Rhône-Poulenc Rorer
(Aventis)
1025, 1063, 1123
Ribosepharm
1200, 1203
Ribozyme Pharmaceuticals
(RPI)
1200, 1208, 1271
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
1257
Sequus Pharmaceuticals
1054, 1057, 1092
Serono
Servier Group
1167, 1200
1200
9
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
Shionogi
1057, 1200, 1202
Sicor
1032, 1057
Sicor de Mexico
1032
Transgene
Triangle Pharmaceuticals
Truman VA Hospital
1198
Siemens Medical Systems
1184
Ultrafine Chemicals
Signal Pharmaceuticals
1097
Unimed Pharmaceuticals
Tularik
Southern Arizona VA
HealthCare System
1205
Southern Research Institute
1196, 1199, 1200
Southwest Oncology Group
(SWOG)
1163
Sparta Pharmaceuticals
1035, 1069, 1098
Spectral Imaging
1081
SR Pharma
1200
SRI International
1063
St. Luke’s Medical Center
1023
Stanford University
1213
Stehlin Foundation for
Cancer Research 1049, 1063, 1201
STS Particles
1035
Sugen
1200, 1209
Sumitomo
1201
Sun Hill Glucose
1030
SUNY
1036
University of Copenhagen
1236, 1237
University Medical
School of Pecs
1202
University of Delaware
Uppsala University
1146
1132
University of Florida
UroCor
1252
1039, 1192, 1201
1097
Unita Operativa di
Oncologia Medica
Unitech
1170
1058
Universita Cattolica
del Sacro Cuore
Universita degli Studi
Université de Montreal
University College
London
University Hospital,
Groningen
1123, 1197
University of Gatzemeier
1122
University of Iowa
1033
University of London,
School of Pharmacy
1057
University of Louisville
School of Medicine
University of Mainz
1178
1146, 1153
1272
1118, 1200
1124, 1177
University Hospital Nijmegen
(The Netherlands)
1251
University Medical Center
Nijmegen (The
Netherlands)
1255, 1256
University Hospital,
Rotterdam
1273
University of Kentucky 1063, 1201
1035, 1055
1095, 1096
SmithKline Beecham
1049, 1055, 1093, 1097,
1100, 1118, 1122, 1124, 1165
1247
1195, 1201
Sidney Kimmel
Cancer Center
SkyPharma
10
Tokushima Bunri University
SEPTEMBER 2000
1222
1144
U.S. Bioscience
1046, 1055, 1101, 1121
Uath State University
1039
VA Northern CA Health
Care System
1120, 1210
Valentis
1202
1182
ValiGen
1273
1166
Vanderbilt Cancer Center
1052
University of Maryland
1081, 1142, 1238
Vanderbilt University
1053, 1174, 1209, 1220
University of Massachusetts
1272, 1278
Veterans Affairs Hospital,
Durham
1153, 1176
University of Medicine and
Dentistry of New Jersey
(UMDNJ)
Veterans’ General
Hospital-Taipei
1177
1269
ViaCirQ
1184
University of Miami School
of Medicine
1266
Vincent T. Lombardi Cancer
Research Center
1215
University of Michigan
1033, 1081, 1244, 1275
Vion
1202
Virgen del Rocío Hospital
1123
University of Milan
1147
University of Minnesota
School of Medicine
Virgen de la Victoria
Hospital
1123
1147
Virginia Tech
1036
University of Missouri
1132
Virogenetics
1215
1193
Viventia Biotech
1202
University Hospital,
Yugoslavia
1169
University of Montreal
University Hospitals,
Münster and Greifswald
1120
University of
North Carolina
VivoRx
1245, 1246
1037
Vysis
1252, 1263
University of Alabama at
Birmingham
1233, 1277
University of Ottawa
1207
Wadley Institutes
University of Padua
1115
Walther Cancer Institute
SuperGen
1032, 1035, 1049, 1057, 1063,
1069, 1098, 1193, 1201, 1206
University of Alberta
University of Pennsylvania
1039, 1058, 1183
Warner-Lambert
Supratek Pharma
University of Basel
(Switzerland)
University of Pennsylvania
Health System’s Institute for
Human Gene Therapy
Wayne State University
1180
Weill Medical College
1217
University of Pittsburgh
1023, 1063, 1082, 1121, 1130,
1162, 1196, 1242, 1252, 1260
West Virginia University
1238
University of South Florida
1245
Syren Pharmaceuticals
1057
Taiho Pharmaceutical
1063, 1069, 1097,
1192, 1193, 1195, 1200, 1201
Takara Shuzo
1214, 1218
University of Arizona
Cancer Center
1241
1205, 1208
1263
University of Bern
1247
University of Berne
1123
University of
British Columbia
1197, 1241
Takeda Chemical Industries
1055, 1091, 1191, 1197, 1198
University of California
1194, 1199, 1200, 1202, 1264
Tampere University
Hospital
University of California Davis
Cancer Center
1210
Tanabe Seiyaku
1151, 1257
1195
TAP Holdings
1055, 1091
Taxolog
1037
Temple University
Cancer Center
1205
Teva
1032
Therakos
1096
Therion Biologics
1201, 1215, 1216
Thomas Jefferson
University
1082, 1272, 1273
Tiefenau Hospital
1171
Titan Pharmaceuticals
1201
University of California
San Diego Cancer Center
1197, 1198
University of California,
Santa Barbara
1236
University of California,
Los Angeles (UCLA)
1113, 1209
University of Cambridge
1264
University of Chicago Cancer
Research Center
1165, 1192, 1203, 1212
University of Cincinnati
1159
University of Colorado
1081, 1200, 1209, 1270, 1275
1246
1081
1196
1173
1068, 1069, 1097
Washington State University 1029
Weston Park Hospital
1120
Whitehead Institute
1195
William Beaumont Hospital
1146
University of Texas
1033, 1035, 1194, 1195,
1196, 1198, 1199, 1202, 1240
Xechem International
1030, 1035, 1037
University of Texas at Austin
Xillix Technologies
1080
Yale Cancer Center
1160
University of Texas Medical
Branch
1272
1184
University of Texas Southwestern
Medical Center
1082
Xenova Group
1063, 1193, 1202
Yale University
1081,
1133, 1202, 1264, 1270, 1275
Yew Tree Pharmaceuticals
1032
York Medical
1202
Zambon Group
1196
Zarix
1069
Zelenka Nursery
1029
Zeneca Diagnostics
1081
University of Wisconsin
Comprehensive Cancer Center
1162, 1208
Zeneca Pharmaceuticals
1090
University of York
Zenyaku Kogyo
University of Tsukuba
University of Vienna
1271
1176, 1255
University of Virginia Health
Sciences Center
1268
University of Washington
1082, 1196, 1218
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
1097
Zentralkrankenhauses SanktJurgen-Strasse (Germany)
1167
1099
FUTURE ONCOLOGY
VOLUME 5, NUMBER 1-12 INDEX
SEPTEMBER 2000
NEW MEDICINE’S ONCOLOGY KNOWLEDGEBASE (
)
IS NOW ON THE WORLD WIDE WEB
NEW MEDICINE’s Oncology KnowledgeBASE
(
) is an invaluable internet resource for anyone
involved with drug development in the oncology field.
NEW MEDICINE has designed a means to keep track of
the incredible amount of information generated daily in
this field, providing a rationally organized compendium of
thousands of pieces of data that can be searched with
ease. Information is presented across many variables,
logically sequestered to reveal activities in a specific arena
of interest. Use of
is an important resource in
the performance of market research/technology assessment studies, in evaluating licensing/collaboration opportunities, in product positioning, and in helping executives
place new information impacting their business in context,
on a daily basis.
FOUR MODULES OF NM/OK
MAY BE NOW ACCESSED ON THE
INTERNET INCLUDING:
New and Marketed Drug Module
These modules currently provide detailed information
on 2,204 drugs in development, marketed drugs, drug
targets, or enabling technologies, for treating cancer and
complications associated with this disease and its treatment, such as anemia, cachexia, edema, emesis, hypercalcemia, infection, mucositis, neutropenia, pain, thrombocytopenia,xerostomia,etc. The database can be searched by:
■ therapeutic indication (malignancy, pain, emesis, infection, etc.)
■
cancer indication (breast, prostate, colorectal, etc.)
■
clinical indication (metastatic melanoma, hormonerefractory prostate cancer, limited-stage small-cell
lung cancer, etc.)
■
clinical status (IND, phase I/II/III/IV, NDA)
■
geographical location where trials are taking place
■
drug category (taxane, topoisomerase I inhibitor,
hormone modulator, etc.)
■
drug type (protein/peptide, natural product, etc.)
■
technology (immunotherapeutic/vaccine, monoclonal
antibody, photodynamic therapy, etc.)
■
mechanism (apoptosis enhancer, antiangiogenic, cell
cycle modulator, etc.)
■
administration route (oral, IV, nasal, intraperitoneal,
intralesional, etc.)
■
delivery mode (liposomal, electroporation, pumps,
implants, etc.)
■
primary developer or affiliate for a complete pipeline
Additionally, records incorporate:
■
patent information
■
price and market size for marketed drugs
■
orphan drug status by indication
■
description of various enabling technologies that may
be used to discover novel cytotoxic/cytostatic, or
immunomodulating agents
Company Module
Also,
profiles 1016 companies/developers
describing their cancer-related activities, and presenting
oncology pipelines.
Marker Module
This module currently comprises 350 records
delineating the role of molecular markers in various
malignancies. Records may be searched by marker
and/or cancer indication.
PLANNED ADDITIONS TO THE DATABASE
is a work in progress. Currently, an AccessTMbased cancer epidemiology module is in development
and will be available in mid 2001. Numerous other
modules are also in development, including a database of
combination trials.
For more information, or a demo of
call NEW MEDICINE at 949-830-0448
or visit our web site at oncologyknowledgebase.com.
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448.
11
A NEW MEDICINE PUBLICATION
VOLUME 5, NUMBER 1-12 INDEX
SEPTEMBER 2000
ORDERING & INQUIRY INFORMATION
FUTURE ONCOLOGY:
FUTURE ONCOLOGY (ISSN 1082-331X) is published as 12 issues
(several double issues) per year, with a free annual index
listing companies/institutions and subjects covered, and a
binder.
❑ YES, I want to order a subscription to FUTURE ONCOLOGY.
Subscription Information:
❑ One-year subscription is $840 U.S. and $900 abroad;
please specify period (from _______ to _______ ). Additional
subscriptions sent in the same envelope are $390 each.
Back Issues:
❑ Volumes V2, V3, V4, and V5 are $2,400 (U.S.) and $2,460
(outside the U.S.).
❑ Volumes V4 and V5 are $1,400 (U.S.) and $1,460 (outside
the U.S.).
Inquiry Information:
❑ Please send me a sample issue of FUTURE ONCOLOGY
❑ Please send me the index of Volumes 1, 2, 3, 4 and 5
Oncology Knowledgebase (
❑ YES, I want to order a order
):
.
is available by subscription only and access is provided via a password. The annual subscription rate is
$2,950 for the first “seat” and $290.00 for each
additional seat for up to 5 seats in the same physical location. Subscription rates for company-wide distribution are
negotiable, based on physical location/IP designation and
number, of users.
Please enter my subscription to
to start on
(date) __________________________ at $2,950.00 ____________
Additional seats # ____________ at $290.00 each __________
Total ___________
All orders must be repaid or accompanied by a signed order form
or P.O. #. Subscriptions to FUTURE ONCOLOGY and
will begin upon receipt of payment. Products are nonreturnable; please, feel free to call for information.
My check for $ _________ is enclosed (make checks payable
to NEW MEDICINE, INC.). Payment must accompany your
order; checks must be drawn on a U.S. bank
Wire Transfer:
Washington Mutual, 400 East Main Street.
Stockton, CA 95290. 800-374-4646. Routing #321180748.
NEW MEDICINE INC. Account #087900008012618
Credit Card: ❑ Visa ❑ AmEx ❑ M/C
Exp. Date: ______
Bill me on P.O. #: ____________________________________________________
Signature: ____________________________________________________________
Name: ________________________________________________________________
Title: ____________________________ Company: ______________________
Address: ______________________________________________________________
City: ____________________________ State: ____________________________
Zip Code: ______________________ Country: ________________________
Telephone: ______________________ Fax: ____________________________
E-mail ________________________________________________________________
Return to: NEW MEDICINE, INC.:
P.O. Box 909 • Lake Forest • CA 92630
Telephone: (949) 830-0448 • Fax: (949) 830-0887
E-mail: [email protected]
Web Sites: www: newmedinc.com
www.oncologyknowledgebase.com
FUTURE ONCOLOGY Staff:
PUBLISHER AND EDITOR:
ASSOCIATE EDITOR:
Katie Siafaca, MS
Timothy Sharon, PhD
ASSISTANT EDITOR:
Inquiry Information:
CIRCULATION:
❑ Please call me for a walk-through the database and a
complimentary pass.
DESIGN & PRODUCTION:
Adele Simon
Amish Kalyani
Jill Burch
EDITORIAL BOARD
Sale of NEW MEDICINE hard copy and electronic
publications is made under the following conditions:
Unauthorized photcopying, distribution or electronic storage is
strickly prohibited. Information incorporated in NEW MEDICINE
products is developed from various sources believed to be reliable. There can be no assurance that such information is accurate in all respects, however, and the publisher cannot be held
liable for errors. Errors, when discovered, will be corrected,
Subsriptions may not be canceled, but may be transferred.
BIOTECHNOLOGY & APPLIED SCIENCES:
James W. Hawkins, PhD, Editor, Antisense Research
and Development
CLINICAL PRACTICE:
Leonard Sender, MD, Medical Director, Hemtopoietic Stem
Cell Program, St. Joseph Hospital Regional Center, Orange, CA
REIMBURSEMENT AND MANAGED CARE:
Elan Rubinstein, PharmD, MPH, Consultant
COPYRIGHT © 2000 NEW MEDICINE INC. 949. 830. 0448